Molecular epidemiology and population immunity of SARS-CoV-2 in Guangdong (2022-2023) following a pivotal shift in the pandemic

Nat Commun. 2024 Aug 15;15(1):7033. doi: 10.1038/s41467-024-51141-y.

Abstract

The SARS-CoV-2 Omicron variant sparked the largest wave of infections worldwide. Mainland China eased its strict COVID-19 measures in late 2022 and experienced two nationwide Omicron waves in 2023. Here, we investigated lineage distribution and virus evolution in Guangdong, China, 2022-2023 by comparing 5813 local viral genomes with the datasets from other regions of China and worldwide. Additionally, we conducted three large-scale serological surveys involving 1696 participants to measure their immune response to the BA.5 and XBB.1.9 before and after the corresponding waves. Our findings revealed the Omicron variants, mainly the BA.5.2.48 lineage, causing infections in over 90% of individuals across different age groups within a month. This rapid spread led to the establishment of widespread immunity, limiting the virus's ability to further adaptive mutation and dissemination. While similar immune responses to BA.5 were observed across all age groups after the initial wave, children aged 3 to 11 developed a stronger cross immune response to the XBB.1.9 strain, possibly explaining their lower infection rates in the following XBB.1 wave. Reinfection with Omicron XBB.1 variant triggered a more potent neutralizing immune response among older adults. These findings highlight the impact of age-specific immune responses on viral spread in potential future waves.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • COVID-19* / epidemiology
  • COVID-19* / immunology
  • COVID-19* / virology
  • Child
  • Child, Preschool
  • China / epidemiology
  • Female
  • Genome, Viral* / genetics
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Molecular Epidemiology
  • Pandemics
  • Phylogeny
  • SARS-CoV-2* / genetics
  • SARS-CoV-2* / immunology
  • Young Adult

Substances

  • Antibodies, Viral

Supplementary concepts

  • SARS-CoV-2 variants